{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:23:44Z","timestamp":1779110624193,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00751-8","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:33:38Z","timestamp":1762961618000},"page":"25-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-Dose Triple-Pill of Telmisartan, Amlodipine, and Indapamide for Initial Hypertension Treatment: A GRADE-Assessed Meta-analysis of Randomized Trials"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-0262","authenticated-orcid":false,"given":"Abdalhakim","family":"Shubietah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2875","authenticated-orcid":false,"given":"Mohamed S.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2718-8627","authenticated-orcid":false,"given":"Ahmed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6089-240X","authenticated-orcid":false,"given":"Hamza A.","family":"Abdul-Hafez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5122-8200","authenticated-orcid":false,"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7262-409X","authenticated-orcid":false,"given":"Ibrahim","family":"Elbably","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-0689","authenticated-orcid":false,"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-7177","authenticated-orcid":false,"given":"Mohammed","family":"Mhanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1223\u201349.","journal-title":"Lancet"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441\u201350.","journal-title":"Circulation"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12872-024-04109-1","volume":"24","author":"YL Niriayo","year":"2024","unstructured":"Niriayo YL, Girmay S, Tesfay N, Gidey K, Asgedom SW. Therapeutic inertia and contributing factors among ambulatory patients with hypertension. BMC Cardiovasc Disord. 2024;24:523.","journal-title":"BMC Cardiovasc Disord"},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/HJH.0000000000002381","volume":"38","author":"K Tsioufis","year":"2020","unstructured":"Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens. 2020;38:1016\u201328.","journal-title":"J Hypertens"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77:692\u2013705.","journal-title":"Hypertension"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Associat. J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","volume":"49","author":"A Mahmud","year":"2007","unstructured":"Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents-a preliminary report. Hypertension. 2007;49:272\u20135.","journal-title":"Hypertension"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.jacadv.2025.101883","volume":"4","author":"N Wang","year":"2025","unstructured":"Wang N, Rueter P, Salam A, Huffman MD, Atkins E, Ojji D, et al. Low-dose combinations with 3 or 4 blood pressure-lowering medications for the treatment of hypertension. JACC Adv. 2025;4:101883. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101883.","journal-title":"JACC Adv"},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Rueter P, Atkins E, Webster R, Huffman M, De Silva A, et al. Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis. JAMA Cardiol. 2023;8:606\u201311.","journal-title":"JAMA Cardiol"},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1007\/s00210-025-03790-z","volume":"398","author":"MS Elgendy","year":"2025","unstructured":"Elgendy MS, Taha HI, Amin AM, Khlidj Y, Ezz MR, Elgamasy MA, et al. The efficacy and safety of low-dose triple combination for hypertension treatment: a systematic review and meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:7721\u201336. https:\/\/doi.org\/10.1007\/s00210-025-03790-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40261-023-01313-3","volume":"43","author":"M Abuelazm","year":"2023","unstructured":"Abuelazm M, Ali S, Saleh O, Badr A, Altobaishat O, AlBarakat MM, et al. The safety and efficacy of quadruple ultra-low-dose combination (Quadpill) for hypertension treatment: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43:813\u201326.","journal-title":"Clin Drug Investig"},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"E549","DOI":"10.1503\/cmaj.241770","volume":"197","author":"R Goupil","year":"2025","unstructured":"Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197:E549\u201364.","journal-title":"CMAJ"},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2024.18080","volume":"332","author":"DB Ojji","year":"2024","unstructured":"Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, et al. Low-dose triple-pill vs standard-care protocols for hypertension treatment in Nigeria: a randomized clinical trial. JAMA. 2024;332:1070\u20139.","journal-title":"JAMA"},{"key":"751_CR16","unstructured":"Medicines G. George Medicines announces FDA approval of WIDAPLIKTM (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment 2025."},{"key":"751_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"751_CR18","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. 2024."},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:1\u201310.","journal-title":"Syst Rev"},{"key":"751_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27:1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785\u201394.","journal-title":"Biometrics"},{"key":"751_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/sim.4780070807","volume":"7","author":"RF Galbraith","year":"1988","unstructured":"Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889\u201394.","journal-title":"Stat Med"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","volume":"404","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024a;404:1536\u201346.","journal-title":"Lancet"},{"key":"751_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.025","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension. J Am Coll Cardiol. 2024b. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.025.","journal-title":"J Am Coll Cardiol"},{"key":"751_CR27","unstructured":"Anderson C. Pilot phase for the workplace migraine HeadAche Prevention Project (HAPPy - pilot) to investigate in a double-blind randomised factorial trial whether treatment with low-dose combination blood pressure (BP) and cholesterol lowering therapy will reduce mig. Aust New Zeal Clin Trials Regist 2018."},{"key":"751_CR28","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.3390\/jcm14165663","volume":"14","author":"A Hafez","year":"2025","unstructured":"Hafez A, Abdelaziz A, Mansour A, Kamal I, Bakr A, Gadelmawla AF, et al. Efficacy and safety of esaxerenone for essential hypertension: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2025;14:5663.","journal-title":"J Clin Med"},{"key":"751_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009. https:\/\/doi.org\/10.1136\/bmj.b1665.","journal-title":"BMJ"},{"key":"751_CR30","doi-asserted-by":"crossref","unstructured":"Soliman Y, Nazir A, Abuelazm M, Seri A, Mahmoud A, Abdelazeem B. The effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. InBaylor University Medical Center Proceedings 2024 Jul 3 (Vol. 37, No. 4, pp. 700-704). Taylor & Francis.","DOI":"10.1080\/08998280.2024.2346409"},{"key":"751_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-025-00720-1","author":"UG Adamu","year":"2025","unstructured":"Adamu UG, Mojela K, Adamu EU, Ojji D, Tsabedze N. Efficacy and safety of low-dose triple single pill combination versus standard care in the management of hypertension in low-and middle-income countries: a systematic review and meta-analysis of three randomized controlled trials. High Blood Press Cardiovasc Prev. 2025. https:\/\/doi.org\/10.1007\/s40292-025-00720-1.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.119.14223","volume":"75","author":"ML Krogager","year":"2020","unstructured":"Krogager ML, Mortensen RN, Lund PE, B\u00f8ggild H, Hansen SM, Kragholm K, et al. Risk of developing hypokalemia in patients with hypertension treated with combination antihypertensive therapy. Hypertension. 2020;75:966\u201372.","journal-title":"Hypertension"},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfu040","volume":"29","author":"G Spasovski","year":"2014","unstructured":"Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014;29:i1-39.","journal-title":"Nephrol Dial Transplant"},{"key":"751_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/cpt.1562","volume":"106","author":"E Ram\u00edrez","year":"2019","unstructured":"Ram\u00edrez E, Rodr\u00edguez A, Queiruga J, Garc\u00eda I, D\u00edaz L, Mart\u00ednez L, et al. Severe hyponatremia is often drug induced: 10-year results of a prospective pharmacovigilance program. Clin Pharmacol Ther. 2019;106:1362\u201379.","journal-title":"Clin Pharmacol Ther"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1177\/0960327110387455","volume":"30","author":"H Kinoshita","year":"2011","unstructured":"Kinoshita H, Kobayashi K, Yaguramaki T, Yasuda M, Fujiki K, Tomiyama J, et al. Losartan potassium\/hydrochlorothiazide (Preminent\u00ae) and hyponatremia: case series of 40 patients. Hum Exp Toxicol. 2011;30:1409\u201314.","journal-title":"Hum Exp Toxicol"},{"key":"751_CR36","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1111\/j.1755-5922.2011.00286.x","volume":"30","author":"M Glover","year":"2012","unstructured":"Glover M, Clayton J. Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis. Cardiovasc Ther. 2012;30:e219\u201326.","journal-title":"Cardiovasc Ther"},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7861\/clinmedicine.11-5-448","volume":"11","author":"EEA Egom","year":"2011","unstructured":"Egom EEA, Chirico D, Clark AL. A review of thiazide-induced hyponatraemia. Clin Med (Northfield Il). 2011;11:448\u201351.","journal-title":"Clin Med (Northfield Il)"},{"key":"751_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/1319-2442.109574","volume":"24","author":"M Al Qahtani","year":"2013","unstructured":"Al Qahtani M, Alshahrani A, Alskaini A, Abukhalid N, Al Johani N, Al Ammari M, et al. Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. Saudi J Kidney Dis Transplant. 2013;24:281\u20135.","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"751_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","volume":"59","author":"C Bavishi","year":"2016","unstructured":"Bavishi C, Bangalore S, Messerli FH. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction? Prog Cardiovasc Dis. 2016;59:253\u201361.","journal-title":"Prog Cardiovasc Dis"},{"key":"751_CR40","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1283","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Cushman W, de Silva A, Di Tanna GL, Gnanenthiran SR, et al. Rationale for a new low-dose triple single pill combination for the treatment of hypertension. Glob Heart. 2024c. https:\/\/doi.org\/10.5334\/gh.1283.","journal-title":"Glob Heart"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00751-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00751-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00751-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:55:00Z","timestamp":1770548100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00751-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00751-8","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}}]}}